EnginZyme, a Stockholm, Sweden-based cell-free synthetic biology company, raised €6.4m in Series A funding.
The round, which brought total funding to over €10m since 2014, was led by Sofinnova Partners. In conjunction with the funding, Michael Krel, Partner of the Sofinnova Industrial Biotech Fund, will join EnginZyme’s Board of Directors.
The company intends to use the funds to accelerate the development of its technology platform and take its first internal production process to pilot.
Led by CEO Dr. Karim Engelmark Cassimjee, EnginZyme provides a cell-free synthetic biology platform combining enzymatic cascades with packed bed reactors to produce sustainable alternatives to plastics, nylons, rubbers, and the tons of other synthetics that are used on a daily basis by companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances.
FinSMEs
22/04/2020